Wadman Renske I, Jansen Marc D, Stam Marloes, Wijngaarde Camiel A, Curial Chantall A D, Medic Jelena, Sodaar Peter, Schouten Jan, Vijzelaar Raymon, Lemmink Henny H, van den Berg Leonard H, Groen Ewout J N, van der Pol W Ludo
UMC Utrecht Brain Center, Department of Neurology and Neurosurgery, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
MRC Holland BV, 1057 DL Amsterdam, the Netherlands.
Brain Commun. 2020 Jun 8;2(2):fcaa075. doi: 10.1093/braincomms/fcaa075. eCollection 2020.
Clinical severity and treatment response vary significantly between patients with spinal muscular atrophy. The approval of therapies and the emergence of neonatal screening programmes urgently require a more detailed understanding of the genetic variants that underlie this clinical heterogeneity. We systematically investigated genetic variation other than copy number in the locus. Data were collected through our single-centre, population-based study on spinal muscular atrophy in the Netherlands, including 286 children and adults with spinal muscular atrophy Types 1-4, including 56 patients from 25 families with multiple siblings with spinal muscular atrophy. We combined multiplex ligation-dependent probe amplification, Sanger sequencing, multiplexed targeted resequencing and digital droplet polymerase chain reaction to determine sequence and expression variation in the locus. , and gene copy number were determined by multiplex ligation-dependent probe amplification. gene variant analysis was performed using Sanger sequencing and RNA expression analysis of by droplet digital polymerase chain reaction. We identified - hybrid genes in 10% of spinal muscular atrophy patients, including partial gene deletions, duplications or conversions within and genes. This indicates that copies can vary structurally between patients, implicating an important novel level of genetic variability in spinal muscular atrophy. Sequence analysis revealed six exonic and four intronic variants, which were associated with disease severity in individual cases. There are no indications that gene copy number or sequence variants add value in addition to copies in predicting the clinical phenotype in individual patients with spinal muscular atrophy. Importantly, 95% of spinal muscular atrophy siblings in our study had equal copy numbers and structural changes (e.g. hybrid genes), but 60% presented with a different spinal muscular atrophy type, indicating the likely presence of further inter- and intragenic variabilities inside as well as outside the locus. gene copies can be structurally different, resulting in inter- and intra-individual differences in the composition of and gene copies. This adds another layer of complexity to the genetics that underlie spinal muscular atrophy and should be considered in current genetic diagnosis and counselling practices.
脊髓性肌萎缩症患者的临床严重程度和治疗反应差异显著。治疗方法的获批以及新生儿筛查项目的出现,迫切需要更详细地了解导致这种临床异质性的基因变异。我们系统地研究了该基因座中除拷贝数以外的基因变异。数据通过我们在荷兰开展的一项基于人群的脊髓性肌萎缩症单中心研究收集,研究对象包括286例1 - 4型脊髓性肌萎缩症儿童和成人,其中56例来自25个有多例脊髓性肌萎缩症兄弟姐妹的家庭。我们结合多重连接依赖探针扩增、桑格测序、多重靶向重测序和数字液滴聚合酶链反应来确定该基因座的序列和表达变异。通过多重连接依赖探针扩增确定SMN、VAPB和UBE2I基因拷贝数。使用桑格测序进行SMN基因变异分析,并通过液滴数字聚合酶链反应对SMN进行RNA表达分析。我们在10%的脊髓性肌萎缩症患者中鉴定出SMN - VAPB杂交基因,包括SMN和VAPB基因内的部分基因缺失、重复或转换。这表明患者之间SMN拷贝在结构上可能存在差异,提示脊髓性肌萎缩症存在一个重要的新的基因变异水平。序列分析揭示了6个外显子和4个内含子SMN变异,个别病例中这些变异与疾病严重程度相关。没有迹象表明在预测脊髓性肌萎缩症个体患者的临床表型时,除了SMN拷贝数外,SMN基因拷贝数或序列变异会增加价值。重要的是,我们研究中95%的脊髓性肌萎缩症兄弟姐妹具有相同的SMN拷贝数和结构变化(如杂交基因),但60%表现出不同类型的脊髓性肌萎缩症,这表明在SMN基因座内外可能还存在进一步的基因间和基因内变异。SMN基因拷贝在结构上可能不同,导致个体间和个体内SMN和VAPB基因拷贝组成存在差异。这为脊髓性肌萎缩症的遗传学增加了另一层复杂性,在当前的基因诊断和咨询实践中应予以考虑。